NCT03260894 2025-07-29Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)Incyte CorporationPhase 3 Completed129 enrolled 13 charts
NCT06263231 2025-07-29INVINCIBLE-3Intensity Therapeutics, Inc.Phase 3 Active not recruiting333 enrolled
NCT07087158 2025-07-28A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell CarcinomaImbioray (Hangzhou) Biomedicine Co., Ltd.Phase 2 Not yet recruiting30 enrolled
NCT03592472 2025-04-13A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)Xynomic Pharmaceuticals, Inc.Phase 3 Recruiting413 enrolled
NCT01147822 2025-03-28Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell CarcinomaNovartisPhase 2 Completed367 enrolled 14 charts